Loading company
Exicure, Inc.
XCUR · Nasdaq · ·
Next earnings: November 6, 2026
$1.14-6.6%Sep 29 close
- 1M
- -11.6%
- 6M
- -74.5%
- 1Y
- -72.1%
- 5Y
- -99.4%
XCUR · Nasdaq · ·
Next earnings: November 6, 2026
$1.14-6.6%Sep 29 close
Exicure, Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$1.1M | -$2.6M | +57.23% |
| Profit per share | -$0.18 | -$0.41 | +56.10% |
| Free Cash Flow | -$934K | -$816K | -14.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Exicure, Inc.’s Item 2.02 8-K filed March 25, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Exicure, Inc. has no earnings call transcript available.